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Abstract
Nuclear medicine techniques designed to identify bone metastases are reviewed. They include planar and whole
body, single photon emission tomography (SPET), F-18 Fluorine and FDG, deoxyglucose, positron emission
tomography (PET), bone imaging.
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Introduction
Bone is a metabolically active tissue undergoing remod-
elling in relation to stress and strain with osteoblastic
repair and osteoclastic removal of bone. Uptake of
an agent depends on the blood supply, the capillary
to bone transfer through extra cellular space and the
degree of osteoblastic and osteoclastic activity. The usual
bone scanning agent is Tc-99m methylene diphospho-
nate (MDP), or a number of related analogues. The
uptake of this agent is primarily at the remineralisation
surface of the bone. In bone metastases this is at the
repair surface due to osteoblastic activity in response to
most adenocarcinomas and sarcomas. However, it can be
stated that if the bone infiltration is due to what might
be termed a familiar bone marrow component, such as
plasma cells in myeloma and white cells in leukaemia or
lymphoma, then the response may be muted and only the
addition of early pathological fracture may make the bone
scan positive. However, for most bone metastases the
bone scan is a highly sensitive but not specific technique.
Except in myeloma, it is generally a much more sensitive
technique than the skeletal survey for bone metastases. A
single focal increase of uptake in the context of cancer
may be suggestive of a metastases but cannot be taken as
diagnostic. Multiple lesions at likely sites of metastases
are usually diagnostic. Lung, breast, prostate and renal
cancers account for most bone metastases and over half
of these metastases occur in the spine.
Normal and benign changes
The variations in the normal bone scan need to be
appreciated, such as the symmetrical epiphysial plates in
the child, the increased uptake in joints of the shoulder
and hand in the right-handed person on the right side
and in the left-handed person on the left side. There are
many normal variants: the degree of bone uptake in the
skull, increased uptake at the manubrium sternal junction,
asymmetry of uptake due to rotation and variations in
intensity due to the closeness of the camera to the bone.
There is a range of abnormalities due to benign
changes which are usually but not always easy to identify,
such as focally increased uptake in the maxilla and
mandible due to dental problems, arthropathic changes
at the base of the thumb and bunions on the big
toes. There are a number of artefacts that may be
seen, usually defects due to buckles, jewellery, money,
pacemaker or prosthesis. Contamination may be due to
active urine, or occasionally contaminated radiographer’s
fingers, for example on the image of the skull through
holding the head. These may be able to be washed
off. Renal and urinary activity may cause problems:
This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI
provided to locate the paper.
1470-7330/02/000084 + 03 c© 2002 International Cancer Imaging Society
Nuclear medicine for bone metastases 85
bladder diverticulum, ureterocoele urinary diversion,
pelvic retention, or anomalous site and position of a
kidney. A poor preparation may contain free Tc-99m in
which case the thyroid, stomach and/or salivary gland
activity may be seen. Sites of muscle or other soft tissue
infarction or necrosis may show focal uptake on the bone
scan.
The main problem is the distinction between degen-
erative change and malignancy in the spine. Typically
degenerative change gives uptake on one or other side
of the junction of the vertebral bodies which extends
outside of the line of the vertebral bodies. It is often
seen to the left or the right side of L5, on the vertebral
edges on the concavity of scoliosis or relating to weight-
bearing joints. Osteoporotic crash fractures are usually
seen as a linear change in the vertebra whose intensity
relates to the recentness of the event. The occasional
rib end may show uptake possibly related to trauma.
Cough or osteoporotic fractures may be seen in the
ribs and traumatic fractures tend to lie in a line across
adjacent ribs. A three-phase scan is usually undertaken to
show that a site of osteomyelitis is active on dynamic,
blood pool and three-hour images. Investigation of the
limbs when there is a specific local complaint is usually
undertaken with a three-phase bone scan.
Single photon emission tomography
(SPET)
This is particularly useful in the lower lumbar spine
for distinguishing causes of chronic backache [1,2]. A
metastasis usually affects the whole or the part of the
body of the vertebra, or part of the body and a pedicle,
or a pedicle alone. Occasionally a defect is seen with
the rim of uptake around it. This is commonly noted in
renal metastases. The spine of the vertebra is not usually
involved in bone metastases. Uptake in the spine of the
vertebra may be seen with Paget’s disease when there
is usually a trefoil appearance of uptake in the spinous
process and the two pedicles. Osteoid osteoma may also
show uptake in a spinous process. SPET is useful in
demonstrating facet joint arthropathy, active pars defect
or degenerative changes. SPET is also used for sorting
out the relations of focal uptake seen in the skull and in
evaluating joint disease, for example cartilage tears in the
knee or avascular necrosis in the hip.
Defects in uptake in the bone may be seen with
a number of malignancies, typically lung cancer and
breast cancer and occasionally in myeloma. Also through
a number of benign diseases such as haemangioma,
bone infarct associated with haemoglobinopathies and fat
infiltration as in Gaucher’s disease. More generally, they
are due to local radiotherapy.
Management of patients with cancer
It is generally agreed that in stage I cancers a bone scan
is not required. However, there are two approaches, the
passive and the active. The passive approach likes to have
a baseline bone scan, for example in breast cancer [3] or
prostate cancer at initial evaluation of the patient; the
bone scan is then repeated, for example at six-monthly
intervals independent of symptoms or signs. The active
approach, which is preferred as it reduces the number of
unnecessary bone scans, is to evaluate the patient from
a symptomatic point of view; if bone pain develops a
bone scan is performed. Nevertheless, some authorities
prefer to undertake a bone scan before cancer surgery,
particularly in lung cancer as evidence of metastases
would preclude an operation. In breast cancer this is not
usually the case, since removal of a breast tumour is
usually undertaken whether or not there is evidence of
metastases.
The bone scan may be used as part of an evaluation
protocol for a new cancer therapy. This may require a
bone scan before and at the evaluation time. In prostate
cancer a bone scan would normally be done before radical
prostatectomy is contemplated as part of the staging
procedure. In colorectal cancer bone metastases are rare
until liver and lung involvement has occurred, but local
bone infiltration may be seen.
Serial bone scans may be used to evaluate the effect
of therapy, for example anti androgen therapy in prostate
cancer and anti oestrogen therapy in breast cancer.
On occasions, a ‘flare’ will be seen with local
increase of uptake at the metastatic site before reduction,
particularly in breast cancer [4]. Residual bone scan
abnormality may persist long after active bone metastases
have responded to treatment or stabilised.
F-18 and FDG bone imaging
The increasing availability of bone PET and SPET,
with coincidence counting with a two-headed thick-
crystal camera, has led to the wider application of F-18
DG, deoxyglucose, and F-18 fluorine in evaluating bone
metastases.
FDG does not show normal bone. It identifies active
metastases in marrow as focal increases in uptake, in
contrast with bone marrow imaging with radiolabelled
white cells or colloids, which show defects. It is able
to show metastases that do not cause a reaction on the
bone scan. It has a higher specificity than Tc-99m MDP
for bone metastases as it is less likely to be taken up by
benign bone lesions and by degenerative changes [5–7].
However, in breast cancer a lesser sensitivity for FDG
PET than Tc-99m MDP is reported [8].
F-18 Fluorine does show uptake in normal bone,
but much more in bone invaded by metastases. With
the higher sensitivity and resolution of dedicated PET
systems, its sensitivity and specificity for bone metastases
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are greater than that of Tc-99m MDP [7,9]. Data with these
F-18 tracers for SPET coincidence counting and how that
compares with dedicated PET are not yet available.
Conclusion
In conclusion, radionuclide bone imaging with Tc-99m
MDP is an established method of showing bone
metastases, but may be in decline [10]. The increasing
use of SPET bone imaging and the availability of F-18
tracers are leading to improvements in detection and the
monitoring of their treatment.
Questions
1. After primary treatment for breast or prostate
cancer, should there be: (a) passive serial follow-up
bone scans, e.g. annually; or (b) active use, i.e. only
when signs or symptoms of bone disorder occur?
2. What is the role of bone SPET?
3. Does F-18 or F-18 DG imaging have a place in
symptomatic bone disorder when the bone scan and
radiology are negative?
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